September 5th, 2013
Lancet Formally Retracts Jikei Heart Study of Valsartan
Larry Husten, PHD
The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007. The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simmering controversy over scientific misconduct involving the Novartis blood pressure lowering drug valsartan (Diovan) had come to a full boil. […]
February 2nd, 2013
European Heart Journal Retracts Main Paper of the Kyoto Heart Study
Larry Husten, PHD
The 2009 report of the Kyoto Heart Study on the add-on effect of valsartan in hypertension has been retracted with a terse comment by the editors of the European Heart Journal.
January 8th, 2013
Two Retractions for Embattled Chief Investigator of KYOTO HEART Study
Larry Husten, PHD
The editor of Circulation Journal, the official journal of the Japanese Circulation Society (and not to be confused with the American Heart Association’s [AHA’s] better known Circulation) has announced the retraction of two substudies from the KYOTO HEART Study. The papers, according to the editor, “contain a number of serious errors in data analysis.” The announcement contained no additional information about […]
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy